|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
SG10201801428RA
(en)
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
SG11201608605QA
(en)
|
2014-06-10 |
2016-12-29 |
Curevac Ag |
Methods and means for enhancing rna production
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP4023755B1
(en)
*
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
BR112017009835A2
(pt)
*
|
2014-12-30 |
2017-12-26 |
Curevac Ag |
moléculas de ácido nucleico artificiais
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
WO2016176330A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
WO2016174271A1
(en)
|
2015-04-30 |
2016-11-03 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
DK3303583T3
(da)
|
2015-05-29 |
2020-07-13 |
Curevac Real Estate Gmbh |
Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
US12258567B2
(en)
|
2015-08-28 |
2025-03-25 |
CureVac SE |
Artificial nucleic acid molecules
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
mRNAキャップ類似体およびmRNAキャッピングの方法
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
WO2017109134A1
(en)
|
2015-12-22 |
2017-06-29 |
Curevac Ag |
Method for producing rna molecule compositions
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
US12612654B2
(en)
|
2016-02-12 |
2026-04-28 |
CureVac SE |
Method for analyzing RNA
|
|
WO2017140905A1
(en)
|
2016-02-17 |
2017-08-24 |
Curevac Ag |
Zika virus vaccine
|
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
|
EP3442590A2
(en)
|
2016-04-13 |
2019-02-20 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP4487869A3
(en)
*
|
2016-04-22 |
2025-07-30 |
CureVac SE |
Rna encoding a tumor antigen
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
EP4631970A3
(en)
|
2016-05-04 |
2026-01-07 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
PL3458083T3
(pl)
|
2016-05-18 |
2023-03-13 |
Modernatx, Inc. |
Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
|
|
WO2017212009A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
EP3468537A1
(en)
|
2016-06-14 |
2019-04-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3528821A4
(en)
*
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
BR112019010486A2
(pt)
*
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
WO2018104538A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
EP3568155A4
(en)
|
2017-01-11 |
2020-09-23 |
The Trustees Of The University Of Pennsylvania |
RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11596679B2
(en)
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
JP7722629B2
(ja)
|
2017-07-04 |
2025-08-13 |
キュアバック エスイー |
新規核酸分子
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US20200362382A1
(en)
|
2017-08-18 |
2020-11-19 |
Modernatx, Inc. |
Methods of preparing modified rna
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
SG11202003247RA
(en)
|
2017-11-08 |
2020-05-28 |
Curevac Ag |
Rna sequence adaptation
|
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
EP3773702A2
(en)
*
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
CA3102135A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
BR112021006074A2
(pt)
|
2018-11-05 |
2021-07-20 |
The University Of North Carolina At Chapel Hill |
genes e cassetes de expressão fig4 otimizados e seu uso
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CA3122645A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
KR20210133218A
(ko)
|
2019-01-31 |
2021-11-05 |
모더나티엑스, 인크. |
볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US20230000908A1
(en)
*
|
2019-09-11 |
2023-01-05 |
Ohio State Innovation Foundation |
Engineered cells and uses thereof
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2021154763A1
(en)
|
2020-01-28 |
2021-08-05 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
BR112022015565A2
(pt)
|
2020-02-07 |
2022-09-27 |
Modernatx Inc |
Vacinas de domínio de mrna para sars-cov-2
|
|
CA3178344A1
(en)
|
2020-03-31 |
2021-10-07 |
The Trustees Of The University Of Pennsylvania |
Universal influenza vaccine using nucleoside-modified mrna
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
TWI899203B
(zh)
|
2020-04-09 |
2025-10-01 |
大陸商蘇州艾博生物科技有限公司 |
脂質奈米粒子組成物
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
AU2021301922A1
(en)
|
2020-06-30 |
2023-02-02 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4178544A4
(en)
|
2020-07-08 |
2024-09-25 |
The Trustees of the University of Pennsylvania |
NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
TW202214566A
(zh)
|
2020-08-20 |
2022-04-16 |
大陸商蘇州艾博生物科技有限公司 |
脂質化合物及脂質奈米粒子組合物
|
|
WO2022047325A1
(en)
*
|
2020-08-31 |
2022-03-03 |
The Trustees Of Columbia University In The City Of New York |
Targeting of tgm4 to treat prostate cancer
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
CN116615472A
(zh)
|
2021-01-14 |
2023-08-18 |
苏州艾博生物科技有限公司 |
聚合物缀合的脂质化合物和脂质纳米颗粒组合物
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
AU2022207495A1
(en)
|
2021-01-15 |
2023-08-03 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
US20240100151A1
(en)
|
2021-01-15 |
2024-03-28 |
Moderna TX, Inc. |
Variant strain-based coronavirus vaccines
|
|
CN114908089B
(zh)
*
|
2021-02-08 |
2024-03-15 |
上海细胞治疗集团有限公司 |
3’utr的构建方法和应用
|
|
JP2024511346A
(ja)
|
2021-03-15 |
2024-03-13 |
モデルナティエックス インコーポレイテッド |
Sars-cov-2 mrnaドメインワクチンの治療的使用
|
|
WO2022221335A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
EP4322994A1
(en)
|
2021-04-14 |
2024-02-21 |
ModernaTX, Inc. |
Influenza-coronavirus combination vaccines
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
AU2022281746B2
(en)
|
2021-05-24 |
2025-01-16 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
AU2022294274A1
(en)
|
2021-06-18 |
2024-02-01 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines
|
|
AU2021461416A1
(en)
|
2021-08-24 |
2024-02-22 |
BioNTech SE |
In vitro transcription technologies
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
JP7883580B2
(ja)
|
2021-10-08 |
2026-07-01 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
US20230302112A1
(en)
|
2021-11-05 |
2023-09-28 |
Sanofi |
Respiratory synctial virus rna vaccine
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
US20250002941A1
(en)
|
2021-11-23 |
2025-01-02 |
Sail Biomedicines, Inc. |
A bacteria-derived lipid composition and use thereof
|
|
AR127808A1
(es)
|
2021-11-30 |
2024-02-28 |
Sanofi Pasteur Inc |
Vacunas contra el metapneumovirus humano
|
|
US20250360194A1
(en)
|
2021-12-08 |
2025-11-27 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CA3242439A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
JP2025502599A
(ja)
|
2021-12-23 |
2025-01-28 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023230481A1
(en)
|
2022-05-24 |
2023-11-30 |
Modernatx, Inc. |
Orthopoxvirus vaccines
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
JP2025529906A
(ja)
|
2022-08-22 |
2025-09-09 |
ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド |
コロナウイルスに対するワクチン
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
JP2025536595A
(ja)
|
2022-11-04 |
2025-11-07 |
サノフィ パスツール インコーポレイテッド |
メッセンジャーrnaテール付加の方法
|
|
KR20250099727A
(ko)
|
2022-11-04 |
2025-07-02 |
사노피 파스퇴르 인크 |
호흡기 세포융합 바이러스 rna 백신접종
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
CN120659802A
(zh)
|
2022-12-15 |
2025-09-16 |
赛诺菲巴斯德有限公司 |
mRNA重组加帽酶
|
|
JP2026503216A
(ja)
|
2022-12-23 |
2026-01-28 |
サノフィ パスツール インコーポレイテッド |
メッセンジャーrnaの最適化されたテーリング
|
|
JP2026503676A
(ja)
|
2023-01-27 |
2026-01-29 |
セイル バイオメディシンズ インコーポレイテッド |
修飾脂質組成物およびその使用
|
|
JP2026503718A
(ja)
|
2023-01-30 |
2026-01-29 |
モデルナティエックス インコーポレイテッド |
エプスタイン・バーウイルスmRNAワクチン
|
|
AR132053A1
(es)
|
2023-03-02 |
2025-05-21 |
Sanofi Pasteur |
Composiciones para su uso en el tratamiento de clamidia
|
|
JP2026508405A
(ja)
|
2023-03-07 |
2026-03-10 |
サノフィ パスツール インコーポレイテッド |
Kp34ポリメラーゼを用いたメッセンジャーrnaの製造
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024215721A1
(en)
|
2023-04-10 |
2024-10-17 |
Modernatx, Inc. |
Lyme disease vaccines
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
IL324411A
(en)
|
2023-05-05 |
2026-01-01 |
Sanofi Pasteur Inc |
Preparations for use in the treatment of acne
|
|
US20250009865A1
(en)
|
2023-05-10 |
2025-01-09 |
Sanofi |
Combination respiratory mrna vaccines
|
|
WO2024254552A1
(en)
|
2023-06-08 |
2024-12-12 |
Modernatx, Inc. |
Stabilized flavivirus vaccines
|
|
WO2024263826A1
(en)
|
2023-06-22 |
2024-12-26 |
Modernatx, Inc. |
Sars-cov-2 t cell vaccines
|
|
WO2025003760A1
(en)
|
2023-06-28 |
2025-01-02 |
Sanofi |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025019352A2
(en)
|
2023-07-14 |
2025-01-23 |
Modernatx, Inc. |
Mers-cov mrna vaccines
|
|
WO2025017151A1
(en)
|
2023-07-18 |
2025-01-23 |
Sanofi |
Stable poly(a)-encoding messenger rna templates
|
|
IL325951A
(en)
|
2023-07-19 |
2026-03-01 |
Sanofi Sa |
Porphyromonas gingivalis antigenic constructs
|
|
WO2025029700A1
(en)
|
2023-07-28 |
2025-02-06 |
Modernatx, Inc. |
Vlp enteroviral vaccines
|
|
WO2025034612A1
(en)
|
2023-08-04 |
2025-02-13 |
Modernatx, Inc. |
Varicella-zoster virus mrna vaccine
|
|
EP4771154A2
(en)
|
2023-09-01 |
2026-07-08 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
TW202527960A
(zh)
|
2023-09-06 |
2025-07-16 |
美商賽諾菲巴斯德公司 |
經修飾b型流感血球凝集素多肽及核酸及其用途
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025134071A1
(en)
|
2023-12-22 |
2025-06-26 |
Sanofi |
Malic and glutaric acid based ionizable lipids
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160191A2
(en)
*
|
2024-01-22 |
2025-07-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for autonomous rna switches for translational control
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025226656A1
(en)
|
2024-04-23 |
2025-10-30 |
Modernatx, Inc. |
Hepatitis b virus mrna vaccines
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026027730A1
(en)
|
2024-07-31 |
2026-02-05 |
Sanofi |
Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026053147A1
(en)
|
2024-09-05 |
2026-03-12 |
Sanofi Pasteur Inc. |
Helper lipids and lnp compositions comprising same
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026080379A1
(en)
|
2024-10-07 |
2026-04-16 |
Modernatx, Inc. |
Lyme disease mrna vaccines
|
|
WO2026093322A1
(en)
|
2024-10-28 |
2026-05-07 |
Sanofi Pasteur Inc. |
Improved dna constructs for manufacturing messenger rna by in vitro transcription
|
|
WO2026104670A1
(en)
|
2024-11-15 |
2026-05-21 |
Sanofi Pasteur |
Variants of epstein-barr virus glycoprotein b, nucleic acids encoding the same, and uses thereof
|
|
WO2026122685A1
(en)
|
2024-12-03 |
2026-06-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2026128724A1
(en)
|
2024-12-11 |
2026-06-18 |
Modernatx, Inc. |
Stabilized flavivirus vaccines
|
|
WO2026142992A1
(en)
|
2024-12-23 |
2026-07-02 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations
|
|
WO2026143086A1
(en)
|
2024-12-24 |
2026-07-02 |
Modernatx, Inc. |
Shuffled polypeptide vaccines
|
|
WO2026165320A1
(en)
|
2025-01-31 |
2026-08-06 |
Sanofi Vaccines US Inc. |
Morpholino cationic lipids
|